

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jul 2010 VOL 153 ISS 4
 FILE LAST UPDATED: 20 Jul 2010 (20100720/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010


CASplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> d que 125
 L3 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
 L4 47225 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON GD/ELS
 L6 2458 SEA FILE=REGISTRY SUB=L4 SSS FUL L3
 L15 STR



Page 1-A

37

Page 1-B

VAR G1=COOH/26/29/31

VAR G2=NH2/40/43

VAR G3=37/38

VAR G4=OH/45/46/48/50

NODE ATTRIBUTES:

CONNECT IS M3 RC AT 24

CONNECT IS E1 RC AT 37

CONNECT IS E1 RC AT 45

CONNECT IS E1 RC AT 47

CONNECT IS E2 RC AT 48

CONNECT IS E1 RC AT 49

CONNECT IS E2 RC AT 50

CONNECT IS E1 RC AT 52

DEFAULT MLEVEL IS ATOM

GGCAT IS SAT AT 37

GGCAT IS SAT AT 38

GGCAT IS SAT AT 47

GGCAT IS SAT AT 48

GGCAT IS UNS AT 49

GGCAT IS SAT AT 50

GGCAT IS SAT AT 52

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 41


STEREO ATTRIBUTES: NONE

L17 16 SEA FILE=REGISTRY SUB=L6 SSS FUL L15

L25 3 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L17

=> d que l34

L3 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L4 47225 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON GD/ELS

L6 2458 SEA FILE=REGISTRY SUB=L4 SSS FUL L3

L27 STR



VAR G1=26/P

NODE ATTRIBUTES:

CONNECT IS M3 RC AT 24

CONNECT IS E2 RC AT 28

DEFAULT MLEVEL IS ATOM

GGCAT IS LOC SAT AT 28

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

L29 86 SEA FILE=REGISTRY SUB=L6 SSS FUL L27

L32 STR



VAR G1=26/P
 REP G2=(0-20) A
 VAR G3=38/44

NODE ATTRIBUTES:

CONNECT IS M3 RC AT 24
 CONNECT IS E2 RC AT 28
 DEFAULT MLEVEL IS ATOM
 GGCAT IS LOC SAT AT 28
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE

L33 14 SEA FILE=REGISTRY SUB=L29 SSS FUL L32
 L34 6 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L33

=> s l25 or l34
 L40 7 L25 OR L34

=> d l40 ibib abs hitstr tot

L40 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1282714 CAPLUS Full-text

DOCUMENT NUMBER: 149:507859

TITLE: Peptide conjugates with signal entities for diagnosing apoptosis

INVENTOR(S): Port, Marc; Rousseaux, Olivier; Muller, Robert; Burtea, Carmen

PATENT ASSIGNEE(S): Guerbet, Fr.

SOURCE: PCT Int. Appl., 73pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2008125420	A2	20081023	WO 2008-EP53447	20080321
WO 2008125420	A3	20081211		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
FR 2914303	A1	20081003	FR 2007-54086	20070328
EP 2137208	A2	20091230	EP 2008-718146	20080321
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				
US 20100143250	A1	20100610	US 2009-593495	20090928
PRIORITY APPLN. INFO.:			FR 2007-54086	A 20070328
			WO 2008-EP53447	W 20080321

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:507859

AB The invention discloses compds. Signal-Link-Peptide [Signal = signal entity; Link = absent, linker; Peptide = peptide comprising an apoptosis-targeting peptide, the apoptosis-targeting peptide being selected from X1-X2-X3-X4-X5-X6 (X1, X2 = leucine, isoleucine; X3, X4 = lysine; X5 = proline; X6 = phenylalanine), advantageously LIKKPF, and functional equivalent thereof; D-A-H-S-X7-S (X7 = phenylalanine, leucine); P-G-D-L-X8-X9 (X8 = serine, valine; X9 = threonine, arginine); H-G-X10-L-S-X11 (X10 = aspartic acid, histidine; X11 = threonine, isoleucine); VLGERG], and the pharmaceutically acceptable salts thereof. Compound preparation is included.

IT 1064074-04-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(peptide conjugates with signal entities for diagnosing apoptosis)

RN 1064074-04-9 CAPLUS

CN Gadolinatate(3-), [N-[4-(carboxy-κO)-4-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]-1-oxobutyl]-L-α-aspartyl-L-alanyl-L-histidyl-L-seryl-L-phenylalanyl-L-serinato(6-)]-, hydrogen (1:2) (CA INDEX NAME)

PAGE 1-B



L40 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1191058 CAPLUS Full-text
DOCUMENT NUMBER: 149:420505
TITLE: Peptide ligands for phosphatidylserine for use in the
diagnostic imaging of apoptosis
INVENTOR(S): Port, Marc; Rousseaux, Olivier; Muller, Robert;
Burtea, Carmen
PATENT ASSIGNEE(S): Guerbet, Fr.
SOURCE: Fr. Demande, 63pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
FR 2914303	A1	20081003	FR 2007-54086	20070328

WO 2008125420 A2 20081023 WO 2008-EP53447 20080321
 WO 2008125420 A3 20081211

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
 CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 2137208 A2 20091230 EP 2008-718146 20080321

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
 SK, TR

US 20100143250 A1 20100610 US 2009-593495 20090928

PRIORITY APPLN. INFO.: FR 2007-54086 A 20070328
 WO 2008-EP53447 W 20080321

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Synthetic peptides that can bind phosphatidylserines and that can be used in the imaging of areas of apoptosis in disease diagnosis are described. These peptides are conjugated with a chelating agent for the delivery of detectable metal ion. The peptide has the general formula: X1X2KKPF (X1, X2 = independently isoleucine or leucine) and may be coupled with a signal peptide. Functional equivalent include: DAHSX7S (X7 = phenylalanine or leucine), PGDLX8X9 (X8 = serine or valine, X9=threonine or arginine), and HGX10LSX11 (X10 = aspartic acid or histidine, X11 = threonine or isoleucine), and VLGERG.

IT ~~1064074-04-9DDF~~, peptide conjugates


RL: ARG (Analytical reagent use); DGN (Diagnostic use); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide ligands for phosphatidylserine for use in diagnostic imaging of apoptosis)


RN 1064074-04-9 CAPLUS

CN Gadolinate(3-), [N-[4-(carboxy-κO)-4-[4,7,10-tris[(carboxy-κO)methyl]-1,4,7,10-tetraazacyclododec-1-yl-κN1,κN4,κN7,κN10]-1-oxobutyl]-L-α-aspartyl-L-alanyl-L-histidyl-L-seryl-L-phenylalanyl-L-serinato(6-)]-, hydrogen (1:2) (CA INDEX NAME)

PAGE 1-A

● 2 H⁺

PAGE 1-B



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2004:1156521 CAPLUS Full-text
 DOCUMENT NUMBER: 142:94136
 TITLE: Preparation of peptidyl gadolinium contrast agents having specific high-relaxivity
 INVENTOR(S): Port, Marc; Rousseaux, Olivier; Corot, Claire; Prigent, Philippe; Lancelot, Eric
 PATENT ASSIGNEE(S): Guerbet, Fr.
 SOURCE: PCT Int. Appl., 179 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2004112839	A2	20041229	WO 2004-IB2193	20040617
WO 2004112839	A3	20050506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2856689	A1	20041231	FR 2003-7694	20030625
EP 1635877	A2	20060322	EP 2004-743857	20040617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20060239926	A1	20061026	US 2004-560830	20040617
JP 2007527857	T	20071004	JP 2006-516592	20040617
PRIORITY APPLN. INFO.:			FR 2003-7694	A 20030625
			US 2003-505423P	P 20030925
			WO 2004-IB2193	W 20040617

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to novel compds. and pharmaceutical compns. that are useful for the diagnosis of many pathologies, in particular cardiovascular, cancer-related and inflammatory pathologies. These compds. comprise a component for targeting a pathol. region linked to a detection component which is effective in diagnostic terms. The detection component is typically an MRI contrast agent, an X-ray contrast agent, or an entity containing a radioisotope or able to be detected by ultrasound or by optical imaging. Compds. Bx-Lz-(HR Ch)y (B is a biovector, L is a linker, HR Ch is a chelate, and x, y, z are 1-8), and their salts with pharmaceutically-acceptable acids or bases, are claimed. Thus, a gadolinium-complexed 1,4,7,10-tetraazacyclododecane derivative was prepared and coupled with peptide H-Pro-Leu-Gly-NHOH. A bis-folate derivative shows very good molar relaxivity (53 mM-1.s-1 at 60 MHz).

IT ~~596121-51-6P~~ ~~596121-92-5P~~
 RL: DGN (Diagnostic use); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of peptidyl gadolinium contrast agents having specific high-relaxivity)


RN 596121-51-6 CAPLUS

CN Gadolate(4-), [α -[2-(4-aminophenyl)ethyl]- α' , α'' , α''' -tris(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(7-)- κ N1, κ N4, κ N7, κ N10, κ O4, κ O7, κ O10]-, tetrasodium (9CI) (CA INDEX NAME)


The diagram shows a Gd³⁺ ion coordinated by a 12-membered macrocyclic ligand. The macrocycle consists of four nitrogen atoms and eight carbon atoms, with two carboxylate groups (-O₂C-) attached to the carbon atoms. A 4-aminophenyl group (-CH₂-CH₂-NH₂) is attached to one of the nitrogen atoms. The Gd³⁺ ion is coordinated by the four nitrogen atoms of the macrocycle, the two carboxylate groups, and two additional water molecules (H₂O). The overall structure is shown in a perspective view, with the Gd³⁺ ion at the center of the coordination sphere.

$$\bullet_4 \text{Na}^+$$


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A




PAGE 2-B




IT 596121-78-7P 596121-90-3P 596121-94-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of peptidyl gadolinium contrast agents having specific
 high-relaxivity)
 RN 596121-78-7 CAPLUS
 CN Gadolate(4-), [$\alpha, \alpha', \alpha''$ -tris(2-carboxyethyl)-
 α''' -[2-(4-nitrophenyl)ethyl]-1,4,7,10-tetraazacyclododecane-
 1,4,7,10-tetraacetato(7-)-
 $\kappa N1, \kappa N4, \kappa N7, \kappa N10, \kappa O1, \kappa O4, \kappa O7$]-,
 tetrahydrogen (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

PAGE 1-A



PAGE 1-B




$$\begin{array}{ccccccccccc}
 & \text{OH} & \text{OH} & \text{OH} & \text{OH} & & & & & & \\
 & | & | & | & | & & & & & & \\
 \text{---} & \text{CH} & \text{---CH} & \text{---CH} & \text{---CH} & \text{---CH}_2 & \text{---OH} & & & & \\
 & & & & & & & & & & \\
 & \text{OH} & \text{OH} & \text{OH} & \text{OH} & & & & & & \\
 & | & | & | & | & & & & & & \\
 \text{---CH}_2 & \text{---CH} & \text{---CH} & \text{---CH} & \text{---CH} & \text{---CH}_2 & \text{---OH} & & & & \\
 & & & & & & & & & & \\
 & & & & & & & & & & \\
 & & & & & & & & & & \\
 \text{---C} & \text{---N---CH}_2 & \text{---CH} & \text{---CH} & \text{---CH} & \text{---CH} & \text{---CH}_2 & \text{---OH} & & & \\
 || & | & & & & & & & & & \\
 \text{O} & \text{CH}_2 & \text{---CH} & \text{---CH} & \text{---CH} & \text{---CH} & \text{---CH}_2 & \text{---OH} & & & \\
 & & | & | & | & | & & & & & \\
 & & \text{OH} & \text{OH} & \text{OH} & \text{OH} & & & & &
 \end{array}$$
$$\begin{array}{ccccccc} & & & \text{OH} & \text{OH} & & \\ & & & | & | & & \\ \text{HO}-\text{CH}_2- & \text{CH} & - & \text{CH} & - & & \\ & | & & | & & & \\ \text{HO}-\text{CH}_2- & \text{CH} & - & \text{CH} & - & \text{CH} & - \\ & | & & | & & | & \\ & \text{OH} & & \text{OH} & & \text{OH} & \end{array}$$
[illegible]


CN Gadolinate(8-), [μ-[α,α''''-[(6-chloro-1,3,5-triazine-2,4-

diyl)bis(imino-4,1-phenylene-2,1-ethanediyl)]bis[α' , α'' , α''' -tris(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato- $\kappa N1, \kappa N4, \kappa N7, \kappa N10, \kappa O4, \kappa O7, \kappa O10$]] (14-)]di-, octahydrogen (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:719481 CAPLUS Full-text

DOCUMENT NUMBER: 139:254313

TITLE: Gadolinium chelate oligomers, their use as contrast products in magnetic resonance imaging and their

synthetic intermediates
 INVENTOR(S): Nachman, Isabelle; Port, Marc; Raynal, Isabelle;
 Rousseaux, Olivier
 PATENT ASSIGNEE(S): Guerbet SA, Fr.
 SOURCE: PCT Int. Appl., 122 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074523	A2	20030912	WO 2003-FR712	20030305
WO 2003074523	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2836916	A1	20030912	FR 2002-2791	20020305
FR 2836916	B1	20040611		
AU 2003233361	A1	20030916	AU 2003-233361	20030305
EP 1480979	A2	20041201	EP 2003-727569	20030305
EP 1480979	B1	20070502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 361299	T	20070515	AT 2003-727569	20030305
US 20070098643	A1	20070503	US 2004-505875	20040903
PRIORITY APPLN. INFO.:			FR 2002-2791	A 20020305
			WO 2003-FR712	W 20030305

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention concerns macrocyclic high-relaxivity gadolinium chelate oligomers of formula W-(A)_m, wherein W, A and m represent a wide variety of polynuclear gadolinium DOTA amide analogs, and their use as contrast products with vascular remanence for magnetic resonance imaging. Example compds., e.g., I, are prepared and exhibit strong relaxivity.

IT 596121-51-6P 596121-52-7P 596121-53-8P
 596121-78-7P 596121-86-7P 596121-88-9P
 596121-90-3P 596121-93-6P 596121-94-7P
 596122-02-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of gadolinium chelate oligomers as contrast agents in magnetic resonance imaging)

RN 596121-51-6 CAPLUS

CN Gadolinate(4-), [α -[2-(4-aminophenyl)ethyl]- α' , α'' , α''' -tris(2-carboxyethyl)-1,4,7,10-

tetraazacyclododecane-1,4,7,10-tetraacetato(7-)-
 $\kappa N1, \kappa N4, \kappa N7, \kappa N10, \kappa O4, \kappa O7, \kappa O10]$ -,
 tetrasodium (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 596121-52-7 CAPLUS
 CN Gadolate(4-), [α -(3-aminopropyl)- $\alpha', \alpha'', \alpha'''$ -
 tris(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-
 tetraacetato(7-)- $\kappa N1, \kappa N4, \kappa N7, \kappa N10, \kappa O4, \kappa O7, \kappa O10]$ -, tetrahydrogen (9CI) (CA INDEX NAME)




RN 596121-53-8 CAPLUS

CN Gadolinium, [[1,1',1'',1''',1'''',1''''',1''''''-[[13-(3-aminopropyl)-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl- κ N3, κ N6, κ N9, κ N15]tris[[4-(carboxy- κ O)-1-oxo-4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-benzenetriyl)bis[carbonyl[(2,3-dihydroxypropyl)imino]]]]hexakis[1-deoxyhexitolato]](3-)]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A




PAGE 2-B



RN 596121-78-7 CAPLUS

CN Gadolinate(4-), [$\alpha, \alpha', \alpha''$ -tris(2-carboxyethyl)-

PAGE 1-A




PAGE 2-A




RN	596121-86-7	CAPLUS
CN	<p>Gadolinium, [[1,1',1'',1''',1'''',1'''''-[[13-[3-[[1,1-dimethylethoxy)carbonyl]amino]propyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-kN3,kN6,kN9,kN15]tris[[4-(carboxy-kO)-1-oxo-4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-benzenetriyl)bis[carbonyl[(2,3-dihydroxypropyl)imino]]]]hexakis[1-deoxyhexitolato]](3-)]-(9CI) (CA INDEX NAME)</p>	


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A




PAGE 2-B




RN 596121-88-9 CAPLUS

CN Gadolate(12-), [μ_3 -[[$\alpha, \alpha', \alpha''$]-[1,3,5-triazine-2,4,6-triyltris(imino-4,1-phenylene-2,1-ethanediyl)]tris($\alpha', \alpha'', \alpha'''$ -tris(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato- $\kappa N1, \kappa N4, \kappa N7, \kappa N10, \kappa O4, \kappa O7, \kappa O10$]] (21-)]tri-, dodecahydrogen (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B




$$\bullet_{12} \text{ H}^+$$

PAGE 1-A




Chemical structure of a gadolinium-based contrast agent, Gd-DTPA-Bz. The central gadolinium ion (Gd^{3+}) is coordinated by three bidentate nitrogen atoms and three bidentate oxygen atoms of a DTPA derivative. The DTPA derivative has a $(CH_2)_3-NH-C(=O)OBu-t$ group, a $CH_2-CH_2-C(=O)NH-CH_2-C(=O)NH-$ group, and a CH_2-CH_2- group. The Bz group is a benzene ring with three bromine atoms and a CH_2- group.


PAGE 1-C




PAGE 2-A




PAGE 2-B




PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 2-A



PAGE 2-B




CRN 76-05-1
CMF C2 H F3 O2




RN 596121-94-7 CAPLUS

CN Gadolate(8-), $[\mu-[[\alpha, \alpha', \alpha'', \alpha''']-(6\text{-chloro-1,3,5-triazine-2,4-diyl})\text{bis(imino-4,1-phenylene-2,1-ethanediyl)}]\text{bis}[\alpha', \alpha'', \alpha''']\text{-tris(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato-}\kappa\text{N1,}\kappa\text{N4,}\kappa\text{N7,}\kappa\text{N10,}\kappa\text{O4,}\kappa\text{O7,}\kappa\text{O10}]](14-)]\text{di-}, \text{octahydrogen (9CI) (CA INDEX NAME)}$

PAGE 1-A




PAGE 1-B




RN 596122-02-0 CAPLUS

CN Gadolinate(8-), $[\mu-[[\alpha, \alpha''''-(6\text{-chloro-}1,3,5\text{-triazine-}2,4\text{-diyl})\text{bis(imino-}3,1\text{-propanediyl)}]\text{bis}[\alpha', \alpha'', \alpha''']\text{-tris(2-carboxyethyl)-}1,4,7,10\text{-tetraazacyclododecane-}1,4,7,10\text{-tetraacetato-}\kappa N1, \kappa N4, \kappa N7, \kappa N10, \kappa O4, \kappa O7, \kappa O10]](14-)]\text{di-}, \text{octahydrogen (9CI)} \quad (\text{CA INDEX NAME})$

PAGE 1-A





OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:718469 CAPLUS Full-text

DOCUMENT NUMBER: 140:205744

TITLE: Thermodynamic and structural properties of Eu³⁺, Gd³⁺ and Tb³⁺ complexes with 1,4,7,10-tetra(2-glutaryl)-1,4,7,10-tetraazacyclododecane in solution: EXAFS, luminescence, potentiometric studies, and quantum calculations

AUTHOR(S): Moreau, Juliette; Guillon, Emmanuel; Aplincourt, Philippe; Pierrard, Jean-Claude; Rimbault, Jean; Port, Marc; Aplincourt, Michel

CORPORATE SOURCE: GRECI, Universite de Reims Champagne-Ardenne, Reims, 51687/2, Fr.

SOURCE: European Journal of Inorganic Chemistry (2003), (16), 3007-3020

CODEN: EJICFO; ISSN: 1434-1948

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The stability of the various complexes formed by racemic solns. of the title ligand (L) with Gd³⁺, Eu³⁺ and Tb³⁺ was investigated by potentiometry. The reaction of complexation proceeds through the quick formation of metastable species leading, after a slow reorganization of the macrocycle, to thermodynamically stable complexes. The mean nos. of water mols. coordinated to the lanthanides were determined by luminescence and EXAFS spectroscopy. This last method, applied to solns. of complexes, allowed to precisely determine the nature of the atoms that surround the metal atom and the distance between the lanthanide ion and the various ligands. These structural data that are in good agreement with the results found using quantum mechanics allow to propose a reaction mechanism, from the hydrated lanthanide ion to the final stable complexes through intermediate species. The specific stability of these final complexes arises from the formation of transitory bonds between the metal ion and two pendant arms, which bear carboxylate groups. The stability consts. of the final complexes have high values [$\log \beta_{110}(\text{EuL5-}) = 24.01$; $\log \beta_{110}(\text{GdL5-}) = 24.03$; $\log \beta_{110}(\text{TbL5-}) = 23.97$]. This induces a

notable in vivo dissociation inertness, which is essential for a potential contrast agent in magnetic resonance imaging.

IT ~~660831-55-0~~ ~~660831-56-1~~

RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)

(europium(3+), gadolinium(3+) or terbium(3+) complexation with tetra(glutaryl)-tetraazacyclododecane in aqueous solution from EXAFS, luminescence, potentiometry and quantum calcs.)


RN 660831-55-0 CAPLUS

CN Gadolate(5-), pentaqua[$\gamma,\gamma',\gamma'',\gamma'''$ -tetracarboxy-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrabutanoato(8-)- $\kappa N1,\kappa N4,\kappa N7,\kappa N10$]-, hexahydrogen (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 660831-56-1 CAPLUS

CN Gadolate(5-), triaqua[γ,γ' -di(carboxy- κO)- γ',γ'' -dicarboxy-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrabutanoato(8-)- $\kappa N1,\kappa N4,\kappa N7,\kappa N10$]-, tetrahydrogen (9CI) (CA INDEX NAME)



●4 H⁺

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2000:881151 CAPLUS Full-text

DOCUMENT NUMBER: 134:36356

TITLE: Preparation of bicyclic polyamino carboxylic acid and amide metal complexes for use in medical imaging

INVENTOR(S): Port, Marc

PATENT ASSIGNEE(S): Guerbet SA, Fr.

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075141	A1	20001214	WO 2000-FR1591	20000608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2794744	A1	20001215	FR 1999-7283	19990609
FR 2794744	B1	20010921		
CA 2376497	A1	20001214	CA 2000-2376497	20000608
CA 2376497	C	20091020		
BR 2000011436	A	20020305	BR 2000-11436	20000608
EP 1183255	A1	20020306	EP 2000-940473	20000608
EP 1183255	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 2001003525	T2	20020521	TR 2001-3525	20000608
US 6440956	B1	20020827	US 2000-589345	20000608
HU 2002001468	A2	20020828	HU 2002-1468	20000608
HU 2002001468	A3	20100128		
JP 2003501430	T	20030114	JP 2001-502423	20000608
AT 233762	T	20030315	AT 2000-940473	20000608
PT 1183255	E	20030630	PT 2000-940473	20000608
ES 2188556	T3	20030701	ES 2000-940473	20000608
RU 2232763	C2	20040720	RU 2002-100125	20000608
CN 1196702	C	20050413	CN 2000-808606	20000608
IL 146304	A	20060410	IL 2000-146304	20000608
MX 2001011439	A	20020604	MX 2001-11439	20011109
NO 2001005991	A	20020206	NO 2001-5991	20011207
NO 321121	B1	20060320		
PRIORITY APPLN. INFO.:			FR 1999-7283	A 19990609
			WO 2000-FR1591	W 20000608
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 134:36356				
GI				




IT 311772-48-2P 311772-49-3P 311772-50-6P
311772-52-8P 312280-07-2P

(preparation of metal chelates of tetraazabicyclopentadecatriene polyaminocarboxylates and amides as medical imaging agents)


CN Gadolinium, [[1,1',1'',1''',1'''',1''''',1''''',1''''',1''''',1''''']
 ''',1''''''''',1''''''''']-(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-
 1(15),11,13-triene-3,6,9-triyl-
 κN3,κN6,κN9,κN15)tris[[4-(carboxy-κO)-1-oxo-
 4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-
 benzenetriyl)]bis(carbonylnitrilo)]dodecakis[1-deoxyhexitolato]](3-)]-
 (9CI) (CA INDEX NAME)

OCC(O)CC(O)CC(O)CC(O)CCN(C(=O)c1cc(Br)cc(Br)c1C(=O)NCC(O)CC(O)CC(O)CC(O)CCO)CCN(C(=O)CCNC(=O)CC)CC


PAGE 1-B




PAGE 1-C



PAGE 2-A




PAGE 2-B




RN 311772-49-3 CAPLUS
 CN Gadolinium, [[1,1',1'',1''',1'''',1''''',1''''''-(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-κN3,κN6,κN9,κN15)tris[[4-(carboxy-κO)-1-oxo-4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-benzenetriyl)bis[carbonyl[(2,3-dihydroxypropyl)imino]]]]hexakis[1-deoxy-D-galactitolato]](3-)]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A




PAGE 2-B




RN 311772-50-6 CAPLUS
 CN Gadolinium, [[1,1',1'',1''',1'''',1''''',1''''''-(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-κN3,κN6,κN9,κN15)tris[[4-(carboxy-κO)-1-oxo-4,1-butanediyl]iminomethylene-4,1-phenylenecarbonylimino(2,4,6-tribromo-5,1,3-benzenetriyl)bis[carbonyl[(2,3-dihydroxypropyl)imino]]]]hexakis[1-deoxy-D-galactitolato]](3-)]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 1-C




$$\text{HO}-\text{CH}_2-\underset{\text{CH}_3}{\text{CH}}-$$
OCC(O)CCN(C(=O)c1ccc(cc1)CNC(=O)CO)C(=O)c2cc(Br)cc(Br)c2C(=O)NCC(O)CC(O)CO
$$\text{OH}$$

PAGE 3-B




RN 311772-52-8 CAPLUS
 CN Gadolinium, [[1,1',1'',1''',1'''',1''''-[(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl- κ N3, κ N6, κ N9, κ N15) tris[[4-(carboxy- κ O)-1-oxo-4,1-butanediyl]iminomethylene-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino(2,4,6-tribromo-5,1,3-benzenetriyl)bis[carbonyl[(2,3-dihydroxypropyl)imino]]]]hexakis[1-deoxy-D-galactitolato]](3-)]- (9CI)
 (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 1-D




PAGE 2-B



PAGE 3-B




PAGE 3-C




RN 312280-07-2 CAPLUS
 CN Gadolinium, [[1,1',1'',1''',1'''',1''''',1''''''-(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-κN3,κN6,κN9,κN15)tris[[4-(carboxy-κO)-1-oxo-4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-benzenetriyl)bis[carbonyl[(2,3-dihydroxypropyl)imino]]]]hexakis[1-deoxy-D-glucitolato]](3-)]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A



PAGE 2-B



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L40 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:392995 CAPLUS Full-text
DOCUMENT NUMBER: 131:67209
TITLE: Metal chelates of macrocyclic polyaminocarboxylic
derivatives and their use for diagnostic imaging
INVENTOR(S): Meyer, Dominique; Port, Marc; Rousseaux, Olivier;
Simonot, Christian
PATENT ASSIGNEE(S): Guerbet SA, Fr.
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 922700	A1	19990616	EP 1998-403108	19981209
EP 922700	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2772025	A1	19990611	FR 1997-15642	19971210
FR 2772025	B1	20000303		
CA 2254261	A1	19990610	CA 1998-2254261	19981209
NO 9805762	A	19990611	NO 1998-5762	19981209
NO 318037	B1	20050124		
AU 9896133	A	19990701	AU 1998-96133	19981209
AU 743361	B2	20020124		
HU 9802849	A2	19991028	HU 1998-2849	19981209
HU 9802849	A3	20010928		
HU 221604	B	20021128		
NZ 333264	A	20000526	NZ 1998-333264	19981209
US 6187285	B1	20010213	US 1998-207513	19981209

IL 127467	A	20010430	IL 1998-127467	19981209
AT 223906	T	20020915	AT 1998-403108	19981209
PT 922700	E	20021231	PT 1998-403108	19981209
ES 2183303	T3	20030316	ES 1998-403108	19981209
CZ 293218	B6	20040317	CZ 1998-4054	19981209
CN 1225922	A	19990818	CN 1998-126925	19981210
CN 1132822	C	20031231		
JP 11279163	A	19991012	JP 1998-377822	19981210
JP 3020938	B2	20000315		
MX 9810499	A	20000331	MX 1998-10499	19981210
BR 9805801	A	20010320	BR 1998-5801	19981210
HK 1021976	A1	20040514	HK 2000-100860	20000212

PRIORITY APPLN. INFO.:

FR 1997-15642



A 19971210

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S):

MARPAT 131:67209

GI



AB Claimed are certain chelates of paramagnetic metal cations, especially Gd³⁺, and their use for diagnostic imaging by magnetic resonance and of radiolabeled metal chelates as scintigraphic agents. Provided are chelate complexes of paramagnetic metal cations containing polyaminocarboxylic acid-substituted cyclen chelating ligands I [$m = 1$ or 2 ; $R' = H$, C1-4 alkyl or hydroxyalkyl, CH_2CO_2H , $CH_2CONZ_1Z_2$ ($Z_1, Z_2 = H$, (hydroxylated) C1-4 alkyl), or $R' = -CH(CO_2H)(CH_2)_mCONHR$; $R = Ph$ derivs. II where $a = 1$ or 2 ; $Z, Z' = bond, CH_2$, various amide derivs., etc., $Z'' = various amide derivs.$; $R_1-R_5 = H, Br, Cl, I$, various amide derivs.], and their pharmacol. acceptable salts.

IT 227598-28-9P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as diagnostic imaging agent)

RN 227598-28-9 CAPLUS


CN Gadolinate(1-), [[1,1',1'',1'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl-κN1,κN4,κN7,κN10)tetrakis[[4-(carboxy-κO)-1-oxo-4,1-butanediyl]iminomethylene-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonyl[(2-

hydroxyethyl)imino]]]tetrakis[1-deoxy-D-glucitolato]](4-)]-, sodium (9CI)
(CA INDEX NAME)


PAGE 1-B




PAGE 1-C




PAGE 2-A




PAGE 2-B




PAGE 3-B




PAGE 3-C



PAGE 3-D




PAGE 4-B



PAGE 5-A




PAGE 5-B



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d que 139
L3 STR




NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L4 47225 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON GD/ELS
L6 2458 SEA FILE=REGISTRY SUB=L4 SSS FUL L3
L36 STR



Page 1-A



Page 2-A

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 31

STEREO ATTRIBUTES: NONE

L38 8 SEA FILE=REGISTRY SUB=L6 SSS FUL L36

L39 2 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L38

=> d l39 ibib abs hitstr tot

L39 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:1156521 CAPLUS Full-text

DOCUMENT NUMBER: 142:94136

TITLE: Preparation of peptidyl gadolinium contrast agents having specific high-relaxivity

INVENTOR(S): Port, Marc; Rousseaux, Olivier; Corot, Claire; Prigent, Philippe; Lancelot, Eric

PATENT ASSIGNEE(S): Guerbet, Fr.

SOURCE: PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004112839	A2	20041229	WO 2004-IB2193	20040617
WO 2004112839	A3	20050506		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
FR 2856689	A1	20041231	FR 2003-7694	20030625
EP 1635877	A2	20060322	EP 2004-743857	20040617
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
US 20060239926	A1	20061026	US 2004-560830	20040617
JP 2007527857	T	20071004	JP 2006-516592	20040617
PRIORITY APPLN. INFO.:			FR 2003-7694	A 20030625
			US 2003-505423P	P 20030925
			WO 2004-IB2193	W 20040617

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The invention relates to novel compds. and pharmaceutical compns. that are useful for the diagnosis of many pathologies, in particular cardiovascular, cancer-related and inflammatory pathologies. These compds. comprise a component for targeting a pathol. region linked to a detection component which is effective in diagnostic terms. The detection component is typically an MRI contrast agent, an X-ray contrast agent, or an entity containing a radioisotope or able to be detected by ultrasound or by optical imaging. Compds. Bx-Lz-(HR Ch)y (B is a biovector, L is a linker, HR Ch is a chelate, and x, y, z are 1-8), and their salts with pharmaceutically-acceptable acids or bases, are claimed. Thus, a gadolinium-complexed 1,4,7,10-tetraazacyclododecane derivative was prepared and coupled with peptide H-Pro-Leu-Gly-NHOH. A bis-folate derivative shows very good molar relaxivity (53 mM-1.s-1 at 60 MHz).

IT 596121-94-7P 596122-03-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of peptidylgadolinium contrast agents having specific high-relaxivity)


RN 596121-94-7 CAPLUS

CN Gadolate(8-), [μ -[[α , α '''-(6-chloro-1,3,5-triazine-2,4-diyl)bis(imino-4,1-phenylene-2,1-ethanediyl)]bis[α ', α '', α '''-tris(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato- κ N1, κ N4, κ N7, κ N10, κ O4, κ O7, κ O10]](14-)]di-, octahydrogen (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 596122-03-1 CAPLUS

CN Gadolate(4-), [μ -[[α 3, α 3'-[(6-chloro-1,3,5-triazine-2,4-diyl)bis(imino-4,1-phenylene-2,1-ethanediyl)]bis[α 6, α 9-bis(2-carboxyethyl)-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetato- κ N3, κ N6, κ N9, κ N15, κ O3,.kappa.06, κ O9]](10-)]di-, tetrahydrogen (9CI) (CA INDEX NAME)

PAGE 1-A

● 4 H⁺

PAGE 1-B



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:719481 CAPLUS Full-text

DOCUMENT NUMBER: 139:254313

TITLE: Gadolinium chelate oligomers, their use as contrast products in magnetic resonance imaging and their synthetic intermediates

INVENTOR(S): Nachman, Isabelle; Port, Marc; Raynal, Isabelle; Rousseaux, Olivier

PATENT ASSIGNEE(S): Guerbet SA, Fr.

SOURCE: PCT Int. Appl., 122 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074523	A2	20030912	WO 2003-FR712	20030305
WO 2003074523	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2836916	A1	20030912	FR 2002-2791	20020305
FR 2836916	B1	20040611		
AU 2003233361	A1	20030916	AU 2003-233361	20030305
EP 1480979	A2	20041201	EP 2003-727569	20030305
EP 1480979	B1	20070502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 361299	T	20070515	AT 2003-727569	20030305
US 20070098643	A1	20070503	US 2004-505875	20040903
PRIORITY APPLN. INFO.:			FR 2002-2791	A 20020305
			WO 2003-FR712	W 20030305
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention concerns macrocyclic high-relaxivity gadolinium chelate oligomers of formula W-(A)_m, wherein W, A and m represent a wide variety of polynuclear gadolinium DOTA amide analogs, and their use as contrast products with vascular remanence for magnetic resonance imaging. Example compds., e.g., I, are prepared and exhibit strong relaxivity.

IT 596121-54-9F
 RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of gadolinium chelate oligomers as contrast agents in magnetic resonance imaging)


RN 596121-54-9 CAPLUS

CN Gadolate(6-), [μ 3-[[α 3, α 3', α 3''-[1,3,5-triazine-2,4,6-triyltris(imino-4,1-phenylene-2,1-ethanediyl)]tris(α 6, α 9-bis(2-carboxyethyl)-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetato- κ N3, κ N6, κ N9, κ N15, κ O3, κ O6, κ O9]](15-))]tri-, hexahydrogen (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 3-A




IT 596121-88-9P 596121-94-7P 596122-03-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of gadolinium chelate oligomers as contrast agents in magnetic
 resonance imaging)
 RN 596121-88-9 CAPLUS
 CN Gadolate(12-), [μ₃-[[α,α''',α''''-[[1,3,5-
 triazine-2,4,6-triyltris(imino-4,1-phenylene-2,1-
 ethanediyl)]tris[α',α'',α'''-tris(2-carboxyethyl)-
 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato-
 κN1,κN4,κN7,κN10,κO4,κO7,κO10]] (21-)]]tri-, dodecahydrogen (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




PAGE 3-A




RN 596121-94-7 CAPLUS

CN Gadolinate(8-), [μ-[[α,α''''-(6-chloro-1,3,5-triazine-2,4-diyl)bis(imino-4,1-phenylene-2,1-ethanediyl)]bis[α',α'',α'''-tris(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato-κN1,κN4,κN7,κN10,κO4,κO7,κO10]](14-)]di-, octahydrogen (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 596122-03-1 CAPLUS

CN Gadolate(4-), [μ-[[α3,α3'-[(6-chloro-1,3,5-triazine-2,4-diyl)bis(imino-4,1-phenylene-2,1-ethanediyl)]bis[α6,α9-bis(2-carboxyethyl)-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetato-κN3,κN6,κN9,κN15,κO3,.kappa.O6,κO9]](10-)]di-, tetrahydrogen (9CI) (CA INDEX NAME)

PAGE 1-A





OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his ful

(FILE 'HOME' ENTERED AT 14:27:01 ON 21 JUL 2010)

FILE 'REGISTRY' ENTERED AT 14:27:06 ON 21 JUL 2010

L1 1 SEA SPE=ON ABB=ON PLU=ON PORPHYRIN/CN
D

FILE 'REGISTRY' ENTERED AT 14:27:42 ON 21 JUL 2010

L2 STR 101-60-0

L*** DEL 3 S L2 EXA SAM

L3 STR L2

L4 47225 SEA SPE=ON ABB=ON PLU=ON GD/ELS

L5 50 SEA SUB=L4 SSS SAM L3

L6 2458 SEA SUB=L4 SSS FUL L3

FILE 'CAPLUS' ENTERED AT 14:29:15 ON 21 JUL 2010

E US2006-560830/APPS

L7 1 SEA SPE=ON ABB=ON PLU=ON (US2006-560830/AP OR US2006-560830/
PRN)

D SCA

D IBIB

E US2003-505423P/APPS

L8 2 SEA SPE=ON ABB=ON PLU=ON US2003-505423P/PRN

D SCA TI

D IBIB TOT

L9 2 SEA SPE=ON ABB=ON PLU=ON L8 AND GADOLIN?

L10 1 SEA SPE=ON ABB=ON PLU=ON L8 AND GADOLIN?/TI

SEL RN

FILE 'REGISTRY' ENTERED AT 14:34:06 ON 21 JUL 2010

L11 123 SEA SPE=ON ABB=ON PLU=ON (103145-74-0/BI OR 108-77-0/BI OR
111431-25-5/BI OR 112245-04-2/BI OR 119-24-4/BI OR 121343-82-6/
BI OR 127903-20-2/BI OR 128184-06-5/BI OR 130707-80-1/BI OR
1499-55-4/BI OR 1947-00-8/BI OR 194920-62-2/BI OR 197151-66-9/B
I OR 197151-68-1/BI OR 197151-79-4/BI OR 226559-04-2/BI OR
294-90-6/BI OR 308240-98-4/BI OR 35661-39-3/BI OR 35737-15-6/BI
OR 391902-84-4/BI OR 391902-85-5/BI OR 407-25-0/BI OR

4246-51-9/BI OR 5231-87-8/BI OR 53464-60-1/BI OR 55941-86-1/BI
 OR 59-30-3/BI OR 596121-50-5/BI OR 596121-51-6/BI OR 596121-55-
 0/BI OR 596121-56-1/BI OR 596121-57-2/BI OR 596121-58-3/BI OR
 596121-59-4/BI OR 596121-70-9/BI OR 596121-71-0/BI OR 596121-72
 -1/BI OR 596121-73-2/BI OR 596121-75-4/BI OR 596121-76-5/BI OR
 596121-77-6/BI OR 596121-78-7/BI OR 596121-90-3/BI OR 596121-92
 -5/BI OR 596121-94-7/BI OR 596122-03-1/BI OR 597559-21-2/BI OR
 597559-94-9/BI OR 597564-14-2/BI OR 69747-36-0/BI OR 7209-00-9/
 BI OR 760-94-1/BI OR 7738-22-9/BI OR 78668-34-5/BI OR 78888-18-
 3/BI OR 819051-18-8/BI OR 819074-44-7/BI OR 819074-45-8/BI OR
 819074-46-9/BI OR 819074-47-0/BI OR 819074-48-1/BI OR 819074-49
 -2/BI OR 819074-50-5/BI OR 819074-51-6/BI OR 819074-52-7/BI OR
 819074-53-8/BI OR 819074-54-9/BI OR 819074-55-0/BI OR 819074-56
 -1/BI OR 819074-57-2/BI OR 819074-58-3/BI OR 819074-59-4/BI OR
 819074-60-7/BI OR 819074-61-8/BI OR 819074-62-9/BI OR 819074-63
 -0/BI OR 819074-64-1/BI OR 819074-65-2/BI OR 819074-66-3/BI OR
 819074-67-4/BI OR 819074-68-5/BI OR 819074-69-6/BI OR 819074-70
 -9/BI OR 819074-71-0/BI OR 819074-72-1/BI OR 819074-73-2/BI OR
 819074-74-3/BI OR 819074-75-4/BI OR 819074-76-5/BI OR 819074-77
 -6/BI OR 819074-78-7/BI OR 819074-79-8/BI OR 819074-80-1/BI OR
 819074-81-2/BI OR 819074-82-3/BI OR 819074-83-4/BI OR 819074-84
 -5/BI OR 819074-85-6/BI OR 819074-86-7/BI OR 819074-87-8/BI OR
 81907

L12 33 SEA SPE=ON ABB=ON PLU=ON L11 AND GD/ELS
 L13 10 SEA SPE=ON ABB=ON PLU=ON L12 AND L6

FILE 'CAPLUS' ENTERED AT 14:35:13 ON 21 JUL 2010

L14 4 SEA SPE=ON ABB=ON PLU=ON L13

FILE 'STNGUIDE' ENTERED AT 14:35:26 ON 21 JUL 2010

FILE 'REGISTRY' ENTERED AT 15:00:10 ON 21 JUL 2010

L15 STR L3
 L16 0 SEA SUB=L6 SSS SAM L15
 L17 16 SEA SUB=L6 SSS FUL L15
 L18 3 SEA SPE=ON ABB=ON PLU=ON L17 AND L11
 D SCA
 L19 10 SEA SPE=ON ABB=ON PLU=ON L6 AND L11
 L20 7 SEA SPE=ON ABB=ON PLU=ON L19 NOT L18
 L21 STR L15
 L22 22 SEA SUB=L6 SSS SAM L21
 L23 570 SEA SUB=L6 SSS FUL L21

FILE 'CAPLUS' ENTERED AT 15:09:18 ON 21 JUL 2010

L24 98 SEA SPE=ON ABB=ON PLU=ON L23
 L25 3 SEA SPE=ON ABB=ON PLU=ON L17
 L26 61 SEA SPE=ON ABB=ON PLU=ON L24 AND (PY<2004 OR AY<2004 OR
 PRY<2004)

FILE 'REGISTRY' ENTERED AT 15:12:15 ON 21 JUL 2010

L27 STR L21
 L28 3 SEA SUB=L6 SSS SAM L27
 L29 86 SEA SUB=L6 SSS FUL L27
 L30 2 SEA SPE=ON ABB=ON PLU=ON L29 AND L11
 D SCA

FILE 'CAPLUS' ENTERED AT 15:16:52 ON 21 JUL 2010

L31 20 SEA SPE=ON ABB=ON PLU=ON L29

FILE 'REGISTRY' ENTERED AT 15:17:03 ON 21 JUL 2010

L32 STR L27
L33 14 SEA SUB=L29 SSS FUL L32

FILE 'CAPLUS' ENTERED AT 15:18:13 ON 21 JUL 2010
L34 6 SEA SPE=ON ABB=ON PLU=ON L33
L35 2 SEA SPE=ON ABB=ON PLU=ON L25 AND L34

FILE 'REGISTRY' ENTERED AT 15:21:05 ON 21 JUL 2010
L36 STR L3
L37 0 SEA SUB=L6 SSS SAM L36
L38 8 SEA SUB=L6 SSS FUL L36

FILE 'CAPLUS' ENTERED AT 15:23:57 ON 21 JUL 2010
L39 2 SEA SPE=ON ABB=ON PLU=ON L38

FILE 'CAPLUS' ENTERED AT 15:24:13 ON 21 JUL 2010
D QUE L25
D QUE L34
L40 7 SEA SPE=ON ABB=ON PLU=ON L25 OR L34
D L40 IBIB ABS HITSTR TOT
D QUE L39
D L39 IBIB ABS HITSTR TOT

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JUL 2010 HIGHEST RN 1233120-12-1
DICTIONARY FILE UPDATES: 19 JUL 2010 HIGHEST RN 1233120-12-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jul 2010 VOL 153 ISS 4

FILE LAST UPDATED: 20 Jul 2010 (20100720/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

CPlus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 16, 2010 (20100716/UP).